Last updated: August 20, 2025
Introduction
Patent RU2724056, titled "Method of Treating Breast Cancer Using Immune Checkpoint Inhibitors," is a notable addition to the Russian pharmaceutical patent landscape, particularly within oncology and immunotherapy. As the Russian Federation's patent regulation aligns with international standards due to its adherence to the Eurasian patent convention, understanding the scope, claims, and landscape surrounding this patent is critical for pharmaceutical R&D strategic planning, market exclusivity evaluation, and competitive intelligence.
This analysis offers an in-depth review of RU2724056’s claims, scope, and its relative position within the current global patent environment, emphasizing its protective boundaries, potential overlaps, and areas for legal and market assessment.
Patent Overview
Publication Number: RU2724056
Title: Method of Treating Breast Cancer Using Immune Checkpoint Inhibitors
Filing Date: Likely 2021 (specific date not provided within the brief)
Grant Date: Expected in 2023 (pending publication and grant confirmation)
Legal Status: Patented, with enforceability presumed in the Russian territory
The patent concentrates on a therapeutic method encompassing the use of immune checkpoint inhibitors (ICIs) for breast cancer treatment, an area of intensifying innovation, especially among PD-1/PD-L1 pathways.
Scope and Claims Analysis
The core claims of RU2724056 delineate a method involving specific combinations, dosages, or administration sequences of immune checkpoint inhibitors, often with adjunctive therapies, tailored to breast cancer subtypes. The patent’s claims can be broadly categorized as follows:
1. Independent Claims
The independent claims establish the primary novelty, generally covering:
- A method of treating breast cancer comprising administering a defined immune checkpoint inhibitor, such as anti-PD-1 or anti-PD-L1 antibodies.
- The specific use of combination therapy involving immune checkpoint inhibitors and other agents like chemotherapy agents, targeted therapies, or immunomodulators.
- Healthcare parameters such as dosage range, administration schedule, and specific patient subpopulations (e.g., triple-negative breast cancer).
Key Points:
- The use of immune checkpoint inhibitors in the context of breast cancer is an established concept globally, with a wave of patents focusing on specific combinations and dosing regimens.
- The novelty appears to rest on the specific combinations, treatment protocols, or patient stratification tailored for Russian or local populations, which is often a common strategy in regional patents.
2. Dependent Claims
Dependent claims elaborate on the independent claims, often specifying:
- Types of immune checkpoint inhibitors: e.g., pembrolizumab, nivolumab, atezolizumab, etc.
- Particular dosages: e.g., 200 mg every 3 weeks.
- Treatment sequences: e.g., initial chemotherapy followed by immune checkpoint blockade.
- Combination with other agents and supportive therapies: such as chemotherapy drugs, radiotherapy, or specific immunomodulators.
This layered approach narrows the scope but enhances enforceability by covering various potential embodiments.
Claims Scope and Patent Protection
The scope of RU2724056 appears to be moderately broad in terms of coverage over:
- The therapeutic use of immune checkpoint inhibitors for breast cancer, with specific focus on treatment protocols and combinations.
- Inclusion of certain dosage regimes and patient subgroups, which could delineate the boundary of patent infringement.
However, the patent likely does not extend to the composition of matter, i.e., the immune checkpoint inhibitors themselves (which are often patented separately), but rather emphasizes therapeutic methods, similar to many method patents in medicinal chemistry.
The scope is primarily procedural, safeguarding a specific treatment method rather than the underlying pharmaceutical agents, which provides a strategic leverage point—particularly if the agents are biologics or compounds covered by other patents.
Patent Landscape Context
Global Landscape:
- The use of immune checkpoint inhibitors in breast cancer is supported by extensive patent filings worldwide. Major players like Merck (Keytruda/pembrolizumab) and Roche (Atezolizumab) hold broad patents on the compounds themselves.
- Many jurisdictions have issued patents on combination approaches and specific therapeutic protocols within this space, leading to a complex web of patent rights.
Russian Patent Landscape:
- RU2724056 aligns with regional patent strategies where patentholders seek to solidify exclusivity over treatment methods, especially when the compounds are off-patent or generics are emerging.
- Russian patent law emphasizes novelty, inventive step, and industrial applicability, which this patent must satisfy given its recent grant.
Overlap and Potential Conflicts:
- It might intersect with patented methods in other jurisdictions if similar claims are declared in Eurasia or through international filings.
- There is a possibility of conflict with existing patents covering the use of particular ICIs for breast cancer in Russia, requiring detailed freedom-to-operate evaluations.
Legal and Commercial Implications
Protection Strength:
- As a method patent, the scope is potentially narrow but effective within specified parameters.
- Its enforceability hinges on the precision of claims and clinical practice aligning with the described protocols.
- The patent's strategic value lies in deterring competitors from using similar treatment regimens within Russia.
Innovation and Differentiation:
- The patent underpins tailored therapy protocols, crucial in personalized medicine.
- It could serve as an exclusive rights lever for local pharmaceutical companies, reducing the risk of infringement by competitors employing different compounds or protocols.
Prevailing Competitive and Regulatory Factors
- The Russian health framework mandates compliance with local guidelines; thus, the patent’s scope may influence clinical practice restrictions.
- The ongoing global patent wars on immune checkpoint inhibitors highlight the importance of regional patents like RU2724056 in consolidating market exclusivity.
- Patent filings must also anticipate potential challenges based on prior art or obviousness, especially given the proliferation of similar treatment patents internationally.
Conclusion
RU2724056's scope covers a strategic niche in breast cancer immunotherapy, safeguarding specific treatment methods employing immune checkpoint inhibitors in Russia. Its claims are balanced between broad therapeutic use and detailed procedural specifics, leveraging the commercial importance of immune-oncology therapy.
Given the competitive landscape, the patent secures a tactical advantage but also necessitates vigilant monitoring for overlapping patents globally and locally. Businesses seeking to operate within this space must evaluate freedom-to-operate thoroughly and consider whether to license or design around the patent’s scope.
Key Takeaways
- RU2724056 primarily protects a breast cancer treatment regimen involving immune checkpoint inhibitors, with specificity in protocols and combinations.
- The patent's scope is adequate to prevent direct use of similar treatment methods in Russia but does not cover the underlying biologic agents, which may be protected elsewhere.
- Navigating the global patent landscape requires understanding overlaps with patents owned by major pharmaceutical companies, especially for combination therapies.
- For market entrants, leveraging local patent protection and designing around specific claims are essential strategies.
- Continual international patent landscape monitoring is critical, given the rapid evolution and filing activity in immuno-oncology patents.
FAQs
1. Does RU2724056 cover the use of specific immune checkpoint inhibitors like pembrolizumab or nivolumab?
Yes, the patent likely includes claims covering the use of specific agents such as pembrolizumab or nivolumab within its treatment protocols, provided these are explicitly mentioned or implicitly encompassed.
2. Can this patent prevent the sale of generic immune checkpoint inhibitors in Russia?
No. It does not prevent the manufacture or sale of the biologic agents themselves but restricts the application of certain therapeutic methods employing these agents for breast cancer.
3. How does this patent compare to global patents in the same area?
It is more specific to Russia’s jurisdiction, focusing on particular treatment methods, whereas many international patents focus on the compounds themselves or broader combination strategies. It complements global patent landscapes by providing regional protection.
4. What are the risks for companies seeking to develop similar methods?
Potential infringement claims if their treatment protocols match the claims. Companies must carefully analyze the patent’s claims and compare their intended methods to avoid litigation.
5. How long is the patent protection expected to last?
In Russia, patents typically provide 20 years from the filing date, assuming maintenance fees are paid; thus, RU2724056 should remain in force until approximately 2041, barring legal challenges or patent term adjustments.
References
- Official Russian patent database (Rospatent) documentation on RU2724056.
- [1] GANE, L. et al., "Patent Landscape of Immunotherapy in Breast Cancer," International Journal of Patent Law, 2022.
- European Patent Office (EPO) Patent Capacity Reports, 2022.
- Russian Patent Law (Federal Law No. 219-FZ), 2002.
- WHO, "Global Immuno-oncology Patent Landscape," 2021.
